Alpha Tau Medical Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K covers the month of May 2026 for Alpha Tau Medical Ltd., a foreign private issuer. The filing primarily serves to disseminate a press release dated May 4, 2026, regarding clinical trial results for the Company's AlphaDaRT® technology in pancreatic cancer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative financial data.
Material Changes
The material update disclosed is the presentation of clinical data at DDW 2026. The Company reported a 100% local disease control rate and a favorable safety profile for AlphaDaRT® in pancreatic cancer trials. No financial material changes versus prior periods are detailed in this document.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the clinical trial results. The filing does not provide specific financial guidance, updated outlooks, or detailed risk factors beyond the standard disclaimer that the information is furnished and not deemed "filed" under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full details of the 100% local disease control rate and safety profile in the attached Exhibit 99.1 press release.
- Confirm the specific patient cohort size and trial phase associated with the DDW 2026 presentation.
- Review the Company's most recent Form 20-F for actual financial position, cash runway, and debt levels, as this 6-K contains no financial data.
- Assess the regulatory pathway and next steps for AlphaDaRT® following these trial results.